Comparison of therapeutic effects of Fenofibrate and Gemfibrozil on Lipid in patients with Diabetes

Comparison of therapeutic effects of Fenofibrate and Gemfibrozil on Lipid profile in patients withType 2 Diabetes Mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201401096710N4

Enrollment

Registered

2014-01-24

Start date

2013-12-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Mixed hyperlipidaemia. Condition 2: Diabetes mellitus. Mixed hyperlipidaemia Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: 1oo or 200 mg Fenofibrate Tablet for 3 month. Intervention 2: 450 or 900 mg Gemfibrozil Tablet for 3 month.

Treatment - Drugs

1oo or 200 mg Fenofibrate Tablet for 3 month

450 or 900 mg Gemfibrozil Tablet for 3 month

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: type 2 diabetes ;LDL chol 200 mg/dl ; Non HDL chol >130 mg/dl. Exclusion criteria: age30,pregnancy;Lactation ;Liver failure ;Renal failure (GFR8%.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Before and 3 month after intervention. Method of measurement: paraclinical.;Cholesterol. Timepoint: Before and 3 month after intervention. Method of measurement: paraclinical.	—

Secondary

Measure	Time frame
Liver aminotransferas(AST & ALT). Timepoint: Before and 3 month after intervention. Method of measurement: Paraclinical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mitra Niafar

Tabriz University of Medical Sciences

dr-niafar@yahoo.comdr.s.ebrahimian@gmail.com+98 41 1335 7850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026